Traders purchased shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on weakness during trading hours on Wednesday. $59.04 million flowed into the stock on the tick-up and $45.73 million flowed out of the stock on the tick-down, for a money net flow of $13.31 million into the stock. Of all stocks tracked, Regeneron Pharmaceuticals had the 26th highest net in-flow for the day. Regeneron Pharmaceuticals traded down ($1.96) for the day and closed at $411.68

A number of research firms recently weighed in on REGN. Piper Jaffray Cos. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Sunday, May 8th. Leerink Swann set a $511.00 target price on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, August 6th. Robert W. Baird restated an “outperform” rating and issued a $505.00 target price (down previously from $526.00) on shares of Regeneron Pharmaceuticals in a research report on Thursday, May 5th. RBC Capital Markets restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Saturday, August 6th. Finally, Cowen and Company restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, June 6th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $477.00.

The firm has a market cap of $43.08 billion and a PE ratio of 64.22. The stock’s 50-day moving average price is $396.20 and its 200 day moving average price is $388.48.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.17. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same period in the prior year, the business posted $2.89 earnings per share. Regeneron Pharmaceuticals’s revenue was up 21.4% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals Inc. will post $10.95 EPS for the current year.

In other news, major shareholder Sanofi acquired 64,731 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, June 14th. The shares were bought at an average cost of $363.86 per share, for a total transaction of $23,553,021.66. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Arthur F. Ryan sold 1,000 shares of the firm’s stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $396.64, for a total value of $396,640.00. Following the transaction, the director now owns 40,500 shares in the company, valued at $16,063,920. The disclosure for this sale can be found here.

Other hedge funds and institutional investors recently made changes to their positions in the company. BlackRock Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 8.3% in the fourth quarter. BlackRock Advisors LLC now owns 262,466 shares of the biopharmaceutical company’s stock worth $142,485,000 after buying an additional 20,224 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 16.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 218,216 shares of the biopharmaceutical company’s stock worth $118,463,000 after buying an additional 31,441 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Regeneron Pharmaceuticals by 5.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 136,447 shares of the biopharmaceutical company’s stock worth $74,078,000 after buying an additional 7,316 shares in the last quarter. American International Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.4% in the fourth quarter. American International Group Inc. now owns 38,434 shares of the biopharmaceutical company’s stock worth $20,865,000 after buying an additional 136 shares in the last quarter. Finally, I.G. Investment Management LTD. increased its position in shares of Regeneron Pharmaceuticals by 1.3% in the fourth quarter. I.G. Investment Management LTD. now owns 20,090 shares of the biopharmaceutical company’s stock worth $10,906,000 after buying an additional 264 shares in the last quarter.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.